Biocardia Inc (BCDA) Stock Price, Quote & News

Latest News on BCDA

Apr 11, 2025, 9:15 AM EDT - 14 days ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Mar 31, 2025, 11:30 PM EDT - 25 days ago

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 1:39 PM EDT - 25 days ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 26, 2025, 4:30 PM EDT - 4 weeks ago

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 21, 2025, 8:30 AM EDT - 5 weeks ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 10, 2025, 9:15 AM EDT - 6 weeks ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Feb 27, 2025, 9:15 AM EST - 2 months ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 13, 2025, 8:30 AM EST - 2 months ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Jan 27, 2025, 9:15 AM EST - 3 months ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Dec 4, 2024, 8:30 AM EST - 5 months ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Nov 13, 2024, 7:49 PM EST - 5 months ago

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

Sep 18, 2024, 8:30 AM EDT - 7 months ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 9, 2024, 4:05 PM EDT - 8 months ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Aug 29, 2024, 8:30 AM EDT - 8 months ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 21, 2024, 7:00 AM EDT - 8 months ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 13, 2024, 7:53 PM EDT - 9 months ago

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:30 PM EDT - 9 months ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Jul 17, 2024, 7:00 AM EDT - 10 months ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jun 7, 2024, 7:00 AM EDT - 11 months ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

May 21, 2024, 5:00 PM EDT - 1 year ago

BioCardia Announces Reverse Stock Split

May 14, 2024, 11:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:02 PM EDT - 1 year ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 1, 2024, 7:00 AM EDT - 1 year ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

Apr 25, 2024, 9:00 AM EDT - 1 year ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Mar 27, 2024, 8:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 4:00 PM EDT - 1 year ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 1 year ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 12, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 4, 2024, 8:00 AM EST - 1 year ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Feb 8, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Jan 31, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Dec 19, 2023, 7:00 AM EST - 1 year ago

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

Dec 18, 2023, 7:16 AM EST - 1 year ago

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

Nov 29, 2023, 7:00 AM EST - 1 year ago

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

Nov 16, 2023, 12:56 PM EST - 1 year ago

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Nov 14, 2023, 7:15 AM EST - 1 year ago

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Nov 8, 2023, 8:08 PM EST - 1 year ago

BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:11 PM EST - 1 year ago

BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 1, 2023, 5:04 PM EDT - 1 year ago

BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

Oct 11, 2023, 6:00 AM EDT - 1 year ago

BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

Sep 6, 2023, 7:15 AM EDT - 1 year ago

BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs

Sep 5, 2023, 7:15 AM EDT - 1 year ago

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Aug 9, 2023, 5:45 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:05 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results

Aug 2, 2023, 7:00 AM EDT - 1 year ago

BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023

Jul 24, 2023, 7:00 AM EDT - 1 year ago

BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

Jul 5, 2023, 7:00 AM EDT - 1 year ago

Market Cap	8.49M
Revenue (ttm)	60,000.00
Net Income (ttm)	-7.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,250.00%
Debt to Equity Ratio	0.00

Volume	53,500
Avg Vol	65,038
Day's Range	N/A - N/A
Shares Out	4.68M
Stochastic %K	71%
Beta	1.21
Analysts	Strong Sell
Price Target	$15.50